CbdMD has started a preclinical human study with researchers at the University of South Carolina. The study will explore the effects of cbdMD’s broad-spectrum cannabinoid blend on sleep, mood, and pain in healthy subjects. The studies will also be measuring key safety markers in healthy humans to augment the company’s safety dossiers for regulatory submissions. The company anticipates that these favorable outcomes will be the basis for future drug research and applications by its therapeutics division. "This partnership reaffirms to our consumers that CbdMD is committed to providing products that make a real impact on their daily lives," says Sibyl Swift, Ph.D., CbdMD’s vice president of scientific and regulatory affairs. "We expect that this study will not only reaffirm that our products are safe and efficacious to support and maintain a healthy lifestyle but will also serve as the foundation for future work to explore the clinical impact of our broad-spectrum cannabinoid blend on areas that matter most to our customers. We want to educate our customers on the benefits of our products and this study will serve as the foundation for that education. This study is another example of our commitment to safety, quality and efficacy for our customers."
Related Articles
BlueSkys Beauty Launches in the U.S.
Kool For Men Debuts Collection of Grooming and Wellness Products